Intelligence Feed event · Equity · 2026-09-12

    Cellectis Schedules September 14 Business Update on Gene Editing and CAR T Pipeline

    Question

    Cellectis Schedules September 14 Business Update on Gene Editing and CAR T Pipeline

    Direct answer

    Cellectis scheduled a comprehensive business update call for Monday, September 14, 2026, to review operational and clinical progress across its gene editing and CAR T cell therapy portfolio. The sessions, scheduled in both English and French, are expected to outline clinical milestone timelines and partnership statuses for its allogeneic oncology candidates.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-12
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Cellectis Schedules September 14 Business Update on Gene Editing and CAR T Pipeline”, revision 1, evidence through 2026-09-12. https://marketontology.com/market-events/2026-09-12/cellectis-schedules-september-14-business-update-on-gene-editing-and-car-t-pipel-edb634

    EQUITY
    Cellectis Schedules September 14 Business Update on Gene Editing and CAR T Pipeline
    Cellectis scheduled a comprehensive business update call for Monday, September 14, 2026, to review operational and clinical progress across its gene editing and CAR T cell therapy portfolio. The sessions, scheduled in both English and French, are expected to outline clinical milestone timelines and partnership statuses for its allogeneic oncology candidates.
    CLLS
    Impact
    56
    SEP 12
    SIG
    88%
    CLLS
    Cellectis Schedules September 14 Business Update on Gene Editing and CAR T Pipeline
    Cellectis scheduled a comprehensive business update call for Monday, September 14, 2026, to review operational and clinical progress across its gene editing and CAR T cell therapy portfolio. The sessions, scheduled in both English and French, are expected to outline clinical milestone timelines and partnership statuses for its allogeneic oncology candidates.
    → Clinical and pipeline disclosures on September 14 will repriced Cellectis' clinical risk discount across its gene editing and allogeneic CAR T assets.
    Impact
    Cellectis scheduled a comprehensive business update call for Monday, September 14, 2026, to review operational and clinical progress across its gene editing and CAR T cell therapy portfolio. The sessions, scheduled in both English and French, are expected to outline clinical milestone timelines and partnership statuses for its allogeneic oncology candidates.
    Affected
    CLLS
    Transmission
    Clinical and pipeline disclosures on September 14 will repriced Cellectis' clinical risk discount across its gene editing and allogeneic CAR T assets.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    CLLSclinical pipeline milestone clarity and runway disclosuresWatchintradayCellectis announced it will host a conference call and webcast on September 14, 2026 to provide a business update.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month